ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Rutin attenuates liver fibrosis via the IRG1-itaconate-Nrf2 axis.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveLiver fibrosis is a common consequence of chronic liver injury, driven by persistent inflammation, oxidative stress, and excessive extracellular matrix deposition. The natural flavonoid rutin possesses antioxidant and anti-inflammatory properties and has shown hepatoprotective potential; however, its anti-fibrotic mechanism remains incompletely understood. This study aimed to investigate the protective effects of rutin and its underlying molecular mechanism in a carbon tetrachloride (CCl₄)-induced mouse model of liver fibrosis, with a particular focus on the role of immune-responsive gene 1 (IRG1).
methodsLiver fibrosis was induced in mice by CCl₄ administration. Hepatic injury, collagen deposition, inflammatory activation, and oxidative stress were evaluated using histological, biochemical, molecular, and transcriptomic approaches. The involvement of IRG1 was assessed by employing IRG1-deficient mice. Direct binding between rutin and IRG1 was examined through molecular docking, molecular dynamics simulations, and the cellular thermal shift assay (CETSA).
resultsRutin treatment markedly alleviated CCl₄-induced hepatic injury, fibrotic deposition, inflammatory cytokine production, and reactive oxygen species accumulation. Mechanistically, rutin directly bound to and stabilized IRG1, which was associated with enhanced IRG1 enzymatic activity and increased endogenous itaconate production. This led to activation of Nrf2-mediated antioxidant signaling and suppression of NLRP3 inflammasome activation. Importantly, the protective effects of rutin were largely abolished in IRG1-deficient mice, confirming that IRG1 is essential for rutin-mediated hepatoprotection.
conclusionThese findings identify rutin as a potential anti-fibrotic agent that targets the IRG1/itaconate axis to coordinate antioxidant and anti-inflammatory responses during liver fibrosis.
Indexed as
Identifiers
42323473What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.